1[1]Malcolm Coppleson. Gynecologic Oncology. Fundamental principles and clinical practice. 2nd ed, New york: Longman, 1992. 286-287.
2[3]Lone K, Petersen MD, Astrid Mamsen, et al. Carcinoma of the cervicalstump. Gynecologic Oncology, 1992, 46: 199-202.
3[4]Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage Ⅱ B - Ⅳ A carcinoma of the cervix with negative para aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. Journal of Clinical Oncology, 1999, 17:1339 - 1348.
4[5]Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent che motherapy compared with pelvic and para- aortic radiation for high - risk cervical cancer. New England Journal of Medicine, 1999, 340:1137 -1143.
5[6]Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin - based radiotherapy and chemotherapy for locally advanced cervical cancer. New England Journal of Medicine, 1999, 340:1144 - 1153.
6[7]Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ⅰ B cervical carcinoma. New England Journal of Medicine, 1999, 340: 1154- 1161.
7[8]Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high - risk early - stage cancer of the cervix. Journal of Clinical Oncology, 2000, 18: 1606- 1603.
